• United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercise and share sales on July 17, 2026.
• A trust acquired 9,500 common shares via option exercise at $135.42.
• The same trust sold 9,500 common shares at weighted-average prices ranging from $528.91 to $542.43.
• Trust holdings fell to 324,443 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000101), on July 20, 2026, and is solely responsible for the information contained therein.